Baidu
map

Lancet Oncology:不良生活方式增加患乳腺癌风险

2013-07-31 刘海英 新华社

日前,牛津大学的研究人员发现,绝经前女性血液中性激素水平越高,她们罹患乳腺癌的风险越大。 在这项研究中,科学家通过对 760 名乳腺癌患者和 1700 名健康女性血液中激素水平相关数据进行分析后得出。 研究人员在最新一期医学杂志《柳叶刀-肿瘤学》(Lancet Oncology)上发表论文称,数据分析表明,性激素水平最高者比最低者罹患乳腺癌的风险增加了 1/5 到 1/3。这些性激素包括雌

日前,牛津大学的研究人员发现,绝经前女性血液中性激素水平越高,她们罹患乳腺癌的风险越大。

在这项研究中,科学家通过对 760 名乳腺癌患者和 1700 名健康女性血液中激素水平相关数据进行分析后得出。

研究人员在最新一期医学杂志《柳叶刀-肿瘤学》(Lancet Oncology)上发表论文称,数据分析表明,性激素水平最高者比最低者罹患乳腺癌的风险增加了 1/5 到 1/3。这些性激素包括雌性激素雌二酮、雌酮,雄性激素雄烯二酮、脱氢表雄酮(DHEAS)以及睾酮。

研究人员还对女性绝经前的生活方式和激素水平的关系进行了研究,结果发现,一些不良生活方式会影响她们的性激素水平,从而间接造成乳腺癌风险的增加。例如,每天吸烟超过 15 支或饮酒超过两杯的女性,其体内雄性激素的水平就会明显高于那些不吸烟喝酒的女性;而饮用酒精饮料越多,体内的雌激素水平也会越高。

研究人员表示,目前他们对性激素水平和乳腺癌之间的关联机制还不完全明晰,尚需要进行更多的研究,而这一新研究成果有助于他们理解乳腺癌生物学机制,对于设计未来的研究方案具有重要意义。

Endogenous Hormones and Breast Cancer Collaborative Group. Sex hormones and risk of breast cancer in premenopausal women: a collaborative reanalysis of individual participant data from seven prospective studies. The Lancet Oncology, 24 July 2013; doi:10.1016/S1470-2045(13)70301-2

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2061391, encodeId=189f206139144, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Sun Sep 29 02:25:00 CST 2013, time=2013-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1674333, encodeId=345116e4333c1, content=<a href='/topic/show?id=e8aa13359b1' target=_blank style='color:#2F92EE;'>#Oncology#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13359, encryptionId=e8aa13359b1, topicName=Oncology)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cb7226973259, createdName=circumcision, createdTime=Sat Dec 21 21:25:00 CST 2013, time=2013-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1864474, encodeId=2f6418644e407, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Sat Apr 05 03:25:00 CST 2014, time=2014-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1770213, encodeId=ab1a1e7021320, content=<a href='/topic/show?id=df9c23e868a' target=_blank style='color:#2F92EE;'>#乳腺癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23786, encryptionId=df9c23e868a, topicName=乳腺癌风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9538161180, createdName=gaoxiaoe, createdTime=Wed Oct 30 02:25:00 CST 2013, time=2013-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1827607, encodeId=9aa0182e607b5, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Fri Jan 10 05:25:00 CST 2014, time=2014-01-10, status=1, ipAttribution=)]
    2013-09-29 sjq027
  2. [GetPortalCommentsPageByObjectIdResponse(id=2061391, encodeId=189f206139144, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Sun Sep 29 02:25:00 CST 2013, time=2013-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1674333, encodeId=345116e4333c1, content=<a href='/topic/show?id=e8aa13359b1' target=_blank style='color:#2F92EE;'>#Oncology#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13359, encryptionId=e8aa13359b1, topicName=Oncology)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cb7226973259, createdName=circumcision, createdTime=Sat Dec 21 21:25:00 CST 2013, time=2013-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1864474, encodeId=2f6418644e407, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Sat Apr 05 03:25:00 CST 2014, time=2014-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1770213, encodeId=ab1a1e7021320, content=<a href='/topic/show?id=df9c23e868a' target=_blank style='color:#2F92EE;'>#乳腺癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23786, encryptionId=df9c23e868a, topicName=乳腺癌风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9538161180, createdName=gaoxiaoe, createdTime=Wed Oct 30 02:25:00 CST 2013, time=2013-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1827607, encodeId=9aa0182e607b5, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Fri Jan 10 05:25:00 CST 2014, time=2014-01-10, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2061391, encodeId=189f206139144, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Sun Sep 29 02:25:00 CST 2013, time=2013-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1674333, encodeId=345116e4333c1, content=<a href='/topic/show?id=e8aa13359b1' target=_blank style='color:#2F92EE;'>#Oncology#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13359, encryptionId=e8aa13359b1, topicName=Oncology)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cb7226973259, createdName=circumcision, createdTime=Sat Dec 21 21:25:00 CST 2013, time=2013-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1864474, encodeId=2f6418644e407, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Sat Apr 05 03:25:00 CST 2014, time=2014-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1770213, encodeId=ab1a1e7021320, content=<a href='/topic/show?id=df9c23e868a' target=_blank style='color:#2F92EE;'>#乳腺癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23786, encryptionId=df9c23e868a, topicName=乳腺癌风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9538161180, createdName=gaoxiaoe, createdTime=Wed Oct 30 02:25:00 CST 2013, time=2013-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1827607, encodeId=9aa0182e607b5, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Fri Jan 10 05:25:00 CST 2014, time=2014-01-10, status=1, ipAttribution=)]
    2014-04-05 minlingfeng
  4. [GetPortalCommentsPageByObjectIdResponse(id=2061391, encodeId=189f206139144, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Sun Sep 29 02:25:00 CST 2013, time=2013-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1674333, encodeId=345116e4333c1, content=<a href='/topic/show?id=e8aa13359b1' target=_blank style='color:#2F92EE;'>#Oncology#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13359, encryptionId=e8aa13359b1, topicName=Oncology)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cb7226973259, createdName=circumcision, createdTime=Sat Dec 21 21:25:00 CST 2013, time=2013-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1864474, encodeId=2f6418644e407, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Sat Apr 05 03:25:00 CST 2014, time=2014-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1770213, encodeId=ab1a1e7021320, content=<a href='/topic/show?id=df9c23e868a' target=_blank style='color:#2F92EE;'>#乳腺癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23786, encryptionId=df9c23e868a, topicName=乳腺癌风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9538161180, createdName=gaoxiaoe, createdTime=Wed Oct 30 02:25:00 CST 2013, time=2013-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1827607, encodeId=9aa0182e607b5, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Fri Jan 10 05:25:00 CST 2014, time=2014-01-10, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=2061391, encodeId=189f206139144, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Sun Sep 29 02:25:00 CST 2013, time=2013-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1674333, encodeId=345116e4333c1, content=<a href='/topic/show?id=e8aa13359b1' target=_blank style='color:#2F92EE;'>#Oncology#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13359, encryptionId=e8aa13359b1, topicName=Oncology)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cb7226973259, createdName=circumcision, createdTime=Sat Dec 21 21:25:00 CST 2013, time=2013-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1864474, encodeId=2f6418644e407, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Sat Apr 05 03:25:00 CST 2014, time=2014-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1770213, encodeId=ab1a1e7021320, content=<a href='/topic/show?id=df9c23e868a' target=_blank style='color:#2F92EE;'>#乳腺癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23786, encryptionId=df9c23e868a, topicName=乳腺癌风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9538161180, createdName=gaoxiaoe, createdTime=Wed Oct 30 02:25:00 CST 2013, time=2013-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1827607, encodeId=9aa0182e607b5, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Fri Jan 10 05:25:00 CST 2014, time=2014-01-10, status=1, ipAttribution=)]
    2014-01-10 howi

相关资讯

JEM:BRCA突变致乳腺癌和卵巢癌的发生

由来自对乳腺癌研究的公主玛格丽特癌症中心坎贝尔家族研究所的Mona Gauthier医生和Tak Mak带领的研究人员,解决了一个关键性难题,那就是BRCA1基因突变,特别是对女性有倾向性,如何致使她们患上乳腺癌和卵巢癌。 发表于7月15日《实验医学杂志》(Journal of Experimental Medicine)的文章作者Mak医生回答说,研究发现雌性激素冲

JCO:乳腺密度或可作为接受他莫昔芬治疗的乳腺癌患者预后标志

他莫昔芬治疗与患者乳腺X线密度降低和生存情况改善有关。然而,在他莫昔芬辅助治疗期间,乳腺密度变化程度是否可作为治疗缓解情况的判定尺度尚不明确。对此,瑞典卡罗琳学院的Per Hall博士等人进行了研究,该研究结果发表于2013年5月28日在线出版的《临床肿瘤学杂志》(Journal of ClinicalOncology)上。 该研究共包括974例绝经后乳腺癌患者,这些患者的基线水平及在随

CEBP:尿液中氧化应激标志物8-oxodG与ER阳性乳腺癌发生相关

氧化应激可能是肿瘤发生有关,因此一项假设研究尿液中氧化应激相关的分子标志物8-oxodG与乳腺癌发生的关系。这是一项巢氏队列研究,收集了24697例50-64岁绝经后妇女,并进行了3-7年的随访。在未发生乳腺癌的人群中,对发生乳腺癌的病例进行匹配。共匹配336例,比较ER阳性和ER阴性乳腺癌发生情况。研究结果显示,尿液中8-oxodG与乳腺癌发生阳性相关。与ER阳性的乳腺癌相关性更大

Cancer Discov:遗传标志物可预测乳腺癌化学预防的效果

两种近日得到阐明的遗传突变可能有助于选择性雌激素受体调节剂药物(SERMs)(如他莫西芬、雷洛昔芬)用于乳腺癌的个体化化学预防。上述发现在线发表于6月13日的《癌症发现》杂志上。研究者称,“这项发现十分重要,因为我们首次发现可以遗传因素可以用于检出那些需要进行药物预防的患者。该研究是由来自梅尔医学中心James Ingle教授所领导。Clifford Hudis博士称:“如果上述研究被证实,这种方

JCO:手术辅助决策或可有益于华人乳腺癌患者

目前乳腺癌(BC)辅助决策(DA)随机研究仅限于DA应用,主要针对西方人群就初始手术提供咨询。但由于未就重建手术及其他人群尚未得到评价,因此这些研究的效果远超过咨询本身。对此,我国香港大学的Wendy W.T.Lam博士等人在针对决定进行BC手术的中国女性患者提供咨询后,建立了一种DA,通过随机对照试验(RCT)对其中相关的即刻乳房重建进行了评价。这项研究结果发表于2013年7月8日在线出版的《临

Ann Oncol:江泽飞等发现循环肿瘤细胞为中国乳腺癌患者生存独立预测因素

在2013年7月14日在线出版的《肿瘤学年鉴》(Annals of Oncology)杂志上,发表了中国军事医学科学院江泽飞教授等人的一项研究成果,该项多中心、双盲、前瞻性研究针对中国转移性乳腺癌(MBC)女性患者,旨在评价循环肿瘤细胞(CTC)测定在预测抗癌治疗手段缓解率方面的潜在应用价值,其中包括人表皮生长因子受体-2(HER-2)靶向药物相关缓解情况、无进展生存期(PFS)以及总生存期(OS

Baidu
map
Baidu
map
Baidu
map